Supplemental Information Q4 FISCAL YEAR 2025 1 Revenue Composition(1) | ($ in thousands) | | | | | | | | | Quarter Ended | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | September 30, | | | | | | December 31, | | September 30, | | | | | | December 31, | | | | 2025 | | June 30, 2025 | | March 31, 2025 | | 2024 | | 2024 | | June 30, 2024 | | March 31, 2024 | | 2023 | | Software and related service revenue | | | | | | | | | | | | | | ...

Investor Presentation November 2022 Fourth Quarter Fiscal Year 2025 Supplemental Presentation November 18, 2025 Cautionary Statement Regarding Forward-Looking Statements Certain matters discussed in this presentation and the accompanying oral presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made based on known events and circumstances at the time of presentation, and as such, are subject to uncertaint ...

Transaction Overview - AkzoNobel and Axalta will combine in an all-stock merger, with Axalta shareholders receiving 0.6539 shares of AkzoNobel for each Axalta share[31] - AkzoNobel expects to pay a special cash dividend to its shareholders equal to €2.5 billion minus regular dividends in 2026 prior to completion[31] - Pro forma ownership will be 55% AkzoNobel shareholders and 45% Axalta shareholders[31] - The transaction is expected to close in late 2026 to early 2027, pending approvals[31] Financial Highlights - The combination aims to create ~$600 million in cost and operational synergies[28] - The combined company's 2024A revenue is $16.9 billion, with $11.6 billion from AkzoNobel and $5.3 billion from Axalta[44, 67] - The combined adjusted EBITDA for 2024A is $3.3 billion, including synergies, with a margin of approximately 19.5%[67] - Adjusted Free Cash Flow is projected at $1.5 billion, including synergies[67] Strategic Benefits - The merger creates a top-tier portfolio with leading positions in key end-markets and globally recognized brands[28] - The combined company will have extensive scale, bringing global capabilities to local customers[28] - The combined R&D investment is approximately $400 million annually, representing about 2.5% of sales[52] - The combined company will have a balanced geographical revenue split, with 43% from EMEA, 24% from APAC, 23% from North America, and 10% from Latin America[48]

Financial Performance - The company's Q2 FY26 net sales reached $1.292 billion, a 34% increase[46] - Adjusted EBITDA for Q2 FY26 was $330 million, up 25%[46] - The adjusted EBITDA margin was 25.5%, a decrease of 190 basis points[46] - Year-to-date free cash flow was $58 million, a 58% decrease[46] Segment Performance - Siding & Trim (S&T) net sales were $696 million, reflecting a 3% organic decrease[55] - Deck, Rail & Accessories (DR&A) net sales were $256 million, up 6%[61] - Australia & New Zealand (ANZ) sales decreased by low-single digits (LSD%) in local currency to $148 million[63] - Europe net sales increased by low-double digits (LDD%) in local currency to $138 million[67] AZEK Integration and Synergies - The company is on track to achieve $125 million of cost synergies[37] - The company expects to exit FY26 annualizing $60 million+ of cost synergies[39] - The company anticipates over $500 million of commercial synergies through material conversion[41, 44]

Amer Sports Third Quarter 2025 FORWARD LOOKING STATEMENTS This presentation contains statements that constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "anticipate," "believe," "may," "will," "expect," "coul ...

Financial Performance - Medtronic reported a strong Q2 FY26 with 6.6% reported revenue growth and 5.5% organic revenue growth[17, 22] - Adjusted diluted EPS grew by 8% year-over-year[13, 20] - The company is raising FY26 revenue guidance by 50 bps to 5.5% and EPS guidance to $5.62-$5.66[13] - Adjusted gross margin expanded by 70 bps due to continued COGS efficiency program execution[15, 22] - The company is expecting ~$185 million tariff impact to COGS[54] Segment Performance - Cardiovascular segment showed strong performance with 9.3% organic growth[15, 21] - Cardiac Ablation Solutions (CAS) grew by 71% year-over-year, with 128% US growth[15, 39, 40] - Neuroscience segment grew by 3.9% organically[21] - Diabetes segment grew by 7.1% organically[21] - Medical Surgical segment grew by 1.3% organically[21] Strategic Initiatives - Medtronic is progressing toward Diabetes business separation by the end of CY26, with a preferred path of IPO and split-off[15, 47] - The company is increasing investments in enterprise growth drivers, organic R&D, and sales/marketing[15] - Medtronic is expecting to add incremental $1 billion revenue from Cardiac Ablation Solutions off FY25 base[33] Product and Market Highlights - The company received US FDA approval for Altaviva for treating urge urinary incontinence[15, 28] - Symplicity Spyral received PMDA approval in Japan and US CMS finalized National Coverage Determination[28, 29] - The company is launching new products and driving commercial execution, expecting growth to accelerate in H2 and beyond[15]

Financial Performance - Total revenue reached $150.5 million in Q3 2025, exceeding guidance of $125 million-$145 million[10, 13] - Revenue increased by 104% year-over-year and 50% quarter-over-quarter[13] - Gross profit was $16.6 million, a 79% increase quarter-over-quarter[13] - Operating loss was $23.9 million, compared to $27.1 million in Q2[13] - Q4 revenue is projected to be between $175 million and $205 million[64, 69] Revenue Streams - Industrial Mining Equipment revenue was $105.8 million, up 69% year-over-year and 61% quarter-over-quarter[15, 17] - Home Mining Equipment revenue was $12.2 million, up 818% year-over-year and 115% quarter-over-quarter[15, 17] - Self-mining revenue was $30.6 million, up 241% year-over-year and 9% quarter-over-quarter[15, 17] Self-Mining Operations - The company held 1,582 bitcoins as of September 30, 2025, with a market value of approximately $179 million[33] - As of October 30, 2025, the company held 1,610 bitcoins[13] - 279 bitcoins were mined in Q3 2025, a 2% decrease quarter-over-quarter[17, 33] - Installed computing power was 9.3 EH/s as of the end of Q3, a 14% increase quarter-over-quarter[17] Computing Power and ASP - Computing power sold reached 10.0 million TH/s (10 EH/s) in Q3 2025[13, 20] - The average selling price (ASP) was $11.8 per TH/s[13, 20] Share Repurchase Program - The company repurchased approximately 5.08 million ADSs for about $3.4 million as of November 18, 2025[83]

KANZHUN LIMITED 3Q 2025 Results Presentation Disclaimer The following document has been prepared by KANZHUN LIMITED ("BOSS Zhipin" or the "Company") solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or ...

Non-GAAP Financial Information Fourth Quarter Fiscal 2025 East San Fernando Valley Transit Corridor Light Rail Los Angeles, California AECOM was appointed by the Los Angeles County Metropolitan Transportation Authority as the lead designer on the East San Fernando Valley Light Rail Transit project, providing engineering, architectural and design services for the 6.7-mile track extension. AECOM was appointed to Phase 2 work in Q4. Disclosures Forward-Looking Statements All statements in this communication ot ...

Promises Made, Promises Kept November 2025 0 Disclaimer The analyses and conclusions of Pershing Square Capital Management, L.P. ("Pershing Square") contained in this presentation are based on publicly available information. Pershing Square recognizes that there may be confidential or otherwise nonpublic information in the possession of the companies discussed in this presentation that could lead these companies and others to disagree with Pershing Square's analyses, conclusions and opinions. This presentat ...